Sign Up Now to Download a Free Research Report on IMGN
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? ImmunoGen, Inc
ImmunoGen shares declined 16 percent after reporting losses widened to $25.2 million in the fiscal first quarter, from to a net loss of $19.5 million in the year-ago quarter. The company expects to file for marketing approval of its cancer drug T-DM1 in 2015.
Going forward ... (see research report)
Subscribe to News Feeds